// App-Quantinova.ai

P359 : A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration

Researchers

Presenter

  • A Rowley

Principal Investigators

  • M Taylor

  • A Duggal

  • M Foster

  • S Sirohi

  • Y Solanke

  • C Walshe

  • M Fyfe

  • S Webber

  • S Travis

Medical Centers

  • TopiVert Pharma Ltd., London, UK

  • Oxford University Hospital, Translational Gastroenterology Unit, Oxford, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Pharmacodynamics

  • Double Blind/Blinded

  • Controlled

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved